ClinicalTrials.gg

Program

arlocabtagene autoleucel

Also written as “BMS-986393”, “Arlocabtagene Autoleucel” and “CC-95266”.

Its studies are mostly in Multiple Myeloma, led by Bristol-Myers Squibb.

Furthest: phase 3, since Sep 24, 20243 company-led studies, 2 open or runningNext primary completion: Dec 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb32 open or runningphase 3since Sep 24, 2024Dec 14, 2020Dec 30, 2027phase 3 · NCT06615479
  • Named in Bristol-Myers Squibb’s own pipeline as arlo-cel, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 14, 2020First study: phase 1 study in Multiple MyelomaFirst studyNCT04674813 · 130 enrolled · United States
  2. Feb 28, 2024Phase 2 study in Multiple MyelomaNCT06297226 · 230 planned · United States, Australia, Canada and more
  3. Sep 24, 2024Phase 3 study in RecurrenceNCT06615479 · 440 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 30, 2027Primary completion: phase 3 study in RecurrenceNCT06615479

TargetBeta

“A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human G-protein coupled receptor family C group 5 member D (GPRC5D), with potential immunostimulating and antineoplastic activities. Upon leukapheresis…”NCIt, read by Claude

Other programs on GPRC5D

ProgramCompanyFurthest phaseStudies
ramantamigJohnson & Johnsonphase 38
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
QLS4131ruleQilu Pharmaceuticalphase 33
QLS32015ruleQilu Pharmaceuticalphase 32
vemzatatug vedotinAstraZenecaphase 21
MBS314 for Injectionrulebeijing-mabworks-biotech-co-ltdphase 21
REGN17372ruleRegeneron Pharmaceuticalsphase 21
Anti-GPRC5D Monoclonal Antibody SAR446523Sanofiphase 11
tunlucabtagene autoleucelBristol-Myers Squibbphase 11
TQB2029Sino Biopharmaceuticalphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06615479Recurrence · United States, Argentina, Australia and more3RecruitingDec 30, 2027440
NCT06297226Multiple Myeloma · United States, Australia, Canada and more2RecruitingJul 31, 2026230
NCT04674813Multiple Myeloma · United States1CompletedDec 22, 2025130

How it is read

Names in the registry

  • “BMS-986393”, 1 entry
  • “Arlocabtagene Autoleucel”, 1 entry
  • “CC-95266”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.